BR112022007313A2 - Conjugado de um agente quelante, e, radiofármaco - Google Patents
Conjugado de um agente quelante, e, radiofármacoInfo
- Publication number
- BR112022007313A2 BR112022007313A2 BR112022007313A BR112022007313A BR112022007313A2 BR 112022007313 A2 BR112022007313 A2 BR 112022007313A2 BR 112022007313 A BR112022007313 A BR 112022007313A BR 112022007313 A BR112022007313 A BR 112022007313A BR 112022007313 A2 BR112022007313 A2 BR 112022007313A2
- Authority
- BR
- Brazil
- Prior art keywords
- chelating agent
- muc5ac
- radiodrug
- conjugate
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine (AREA)
Abstract
CONJUGADO DE UM AGENTE QUELANTE, E, RADIOFÁRMACO. O anticorpo humanizado anti-MUC5AC marcado com RI é um complexo de um agente quelante quelatado por radionuclídeo e um anticorpo (o radionuclídeo é um nuclídeo metálico que emite raios a ou pósitrons, e o anticorpo é um anticorpo humanizado que se liga especificamente a MUC5AC) e é muito útil no tratamento e/ou diagnóstico de doenças nas quais MUC5AC é superexpressa, especialmente câncer, devido à excelente especificidade para MUC5AC e capacidade de se acumular em tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019191562 | 2019-10-18 | ||
PCT/JP2020/039074 WO2021075544A1 (ja) | 2019-10-18 | 2020-10-16 | Ri標識されたヒト化抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022007313A2 true BR112022007313A2 (pt) | 2022-07-05 |
Family
ID=75538071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022007313A BR112022007313A2 (pt) | 2019-10-18 | 2020-10-16 | Conjugado de um agente quelante, e, radiofármaco |
Country Status (13)
Country | Link |
---|---|
US (2) | US11369701B2 (pt) |
EP (1) | EP4049684A4 (pt) |
JP (2) | JP7036996B2 (pt) |
KR (1) | KR20220084135A (pt) |
CN (1) | CN114585393A (pt) |
AU (1) | AU2020367415A1 (pt) |
BR (1) | BR112022007313A2 (pt) |
CA (1) | CA3158322A1 (pt) |
IL (1) | IL292133A (pt) |
MX (1) | MX2022004582A (pt) |
TW (1) | TW202128230A (pt) |
WO (1) | WO2021075544A1 (pt) |
ZA (1) | ZA202205226B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230088764A (ko) * | 2020-10-16 | 2023-06-20 | 니혼 메디피직스 가부시키가이샤 | 항her2 항체의 방사성 복합체, 및 방사성 의약 |
EP4327831A1 (en) * | 2021-04-20 | 2024-02-28 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical |
JPWO2022225006A1 (pt) * | 2021-04-21 | 2022-10-27 | ||
TW202400240A (zh) * | 2022-02-15 | 2024-01-01 | 日商日本醫事物理股份有限公司 | 抗vegf抗體的放射性複合體及放射性醫藥 |
WO2024090489A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物の製造方法 |
WO2024090488A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07203974A (ja) | 1994-01-13 | 1995-08-08 | Tosoh Corp | 癌特異的ムチンを認識する抗体の遺伝子断片等 |
JPH115749A (ja) | 1997-06-13 | 1999-01-12 | Tosoh Corp | 癌治療医薬品組成物 |
US8435529B2 (en) * | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
SE0200943D0 (sv) | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
CN102137681B (zh) * | 2008-08-08 | 2014-12-03 | 埃姆诺医药有限公司 | 抗胰腺癌抗体 |
CN102844432A (zh) | 2010-03-24 | 2012-12-26 | 株式会社钟化 | 特异性结合免疫球蛋白的蛋白质以及免疫球蛋白结合性亲和配体 |
WO2013157102A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
US9107960B2 (en) * | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
JP2017503763A (ja) | 2013-12-03 | 2017-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Gcc発現細胞を撮像するための化合物及び組成物 |
CA2948013A1 (en) * | 2014-06-30 | 2016-01-07 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2) |
KR102651537B1 (ko) | 2015-05-20 | 2024-03-25 | 가고시마 유니버시티 | IgG 결합 펩타이드에 의한 항체의 특이적 변형 |
JP6959616B2 (ja) | 2016-06-13 | 2021-11-02 | 国立大学法人 鹿児島大学 | IgG結合ペプチドによる部位特異的RI標識抗体 |
KR20200004861A (ko) * | 2017-05-05 | 2020-01-14 | 퓨전 파마슈티칼즈 인크. | Igf-1r 모노클로날 항체 및 그의 용도 |
WO2018230257A1 (ja) | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
CA3097101A1 (en) | 2018-04-16 | 2019-10-24 | Nihon Medi-Physics Co., Ltd. | Modified antibody and radioactive metal-labelled antibody |
JP7242325B2 (ja) | 2018-04-20 | 2023-03-20 | キヤノン株式会社 | 画像形成装置 |
IL292176A (en) * | 2019-10-18 | 2022-06-01 | Sumitomo Pharma Co Ltd | Humanized antibody and method for using it |
-
2020
- 2020-10-16 WO PCT/JP2020/039074 patent/WO2021075544A1/ja unknown
- 2020-10-16 JP JP2021538348A patent/JP7036996B2/ja active Active
- 2020-10-16 AU AU2020367415A patent/AU2020367415A1/en active Pending
- 2020-10-16 CN CN202080072157.9A patent/CN114585393A/zh active Pending
- 2020-10-16 TW TW109135914A patent/TW202128230A/zh unknown
- 2020-10-16 BR BR112022007313A patent/BR112022007313A2/pt unknown
- 2020-10-16 IL IL292133A patent/IL292133A/en unknown
- 2020-10-16 EP EP20875874.8A patent/EP4049684A4/en active Pending
- 2020-10-16 KR KR1020227016486A patent/KR20220084135A/ko unknown
- 2020-10-16 MX MX2022004582A patent/MX2022004582A/es unknown
- 2020-10-16 CA CA3158322A patent/CA3158322A1/en active Pending
-
2021
- 2021-07-02 US US17/367,077 patent/US11369701B2/en active Active
-
2022
- 2022-03-03 JP JP2022032379A patent/JP2022088398A/ja active Pending
- 2022-05-11 ZA ZA2022/05226A patent/ZA202205226B/en unknown
- 2022-05-26 US US17/825,430 patent/US20230094773A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3158322A1 (en) | 2021-04-22 |
EP4049684A4 (en) | 2023-10-25 |
KR20220084135A (ko) | 2022-06-21 |
AU2020367415A1 (en) | 2022-05-19 |
JPWO2021075544A1 (ja) | 2021-11-04 |
US20230094773A1 (en) | 2023-03-30 |
US20210338852A1 (en) | 2021-11-04 |
US11369701B2 (en) | 2022-06-28 |
MX2022004582A (es) | 2022-07-21 |
JP2022088398A (ja) | 2022-06-14 |
TW202128230A (zh) | 2021-08-01 |
IL292133A (en) | 2022-06-01 |
WO2021075544A1 (ja) | 2021-04-22 |
EP4049684A1 (en) | 2022-08-31 |
CN114585393A (zh) | 2022-06-03 |
ZA202205226B (en) | 2023-11-29 |
JP7036996B2 (ja) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022007313A2 (pt) | Conjugado de um agente quelante, e, radiofármaco | |
BR112018067522A2 (pt) | anticorpos específicos para receptor de poliovírus humano (pvr) | |
BR112021011431A2 (pt) | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit | |
CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
BR112018070636A2 (pt) | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito | |
BR112019023909A8 (pt) | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab | |
DOP2021000238A (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
BR112022021322A2 (pt) | Anticorpo contra nectina-4 e aplicação do mesmo | |
BR112013004056B8 (pt) | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende | |
BR112017021245A2 (pt) | Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo | |
BR112019000071A2 (pt) | conjugados adjuvantes de anticorpo | |
BR112021007902A2 (pt) | Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos | |
BR112012016820A2 (pt) | Metodos para tratamento de cancer de seio | |
BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
BR112017027549A2 (pt) | anticorpo para cd40 | |
CU24644B1 (es) | Conjugados anticuerpo-fármaco para ablación de células madre hematopoyéticas | |
BR112017026027A2 (pt) | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 | |
BR112019009172A2 (pt) | formulações para radioterapia e diagnóstico por imagem. | |
AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
ECSP20063690A (es) | Anticuerpos |